...
首页> 外文期刊>Histopathology: Official Journal of the British Division of the International Academy of Pathology >Overexpression of dedicator of cytokinesis I (Dock180) in ovarian cancer correlated with aggressive phenotype and poor patient survival.
【24h】

Overexpression of dedicator of cytokinesis I (Dock180) in ovarian cancer correlated with aggressive phenotype and poor patient survival.

机译:卵巢癌中胞质分裂抑制剂I(Dock180)的过度表达与侵袭性表型和患者生存不良有关。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AIMS: Dedicator of cytokinesis I (Dock180) is a novel guanine nucleotide exchange factor for Rho guanosine triphosphates (GTPases) important for cell migration. The aim of this study was to evaluate the role of Dock180 in ovarian carcinogenesis. METHODS AND RESULTS: Using immunohistochemistry, real-time polymerase chain reaction and Western blotting, overexpression of Dock180 RNA and protein was demonstrated in the nucleus and cytoplasm of ovarian cancer cell lines (n = 5) and clinical samples of ovarian borderline tumours (n = 21) and invasive cancers (n = 108) when compared with ovarian epithelial cell lines (n = 3) and benign cystadenomas (n = 10) (P < 0.05). High Dock180 cytoplasmic expression in ovarian cancer (n = 108) was associated significantly with serous histological type, high-grade cancer and advanced stage (P < 0.05), as well as poor overall and disease-free survival (P = 0.004). Using multivariate progression analysis, high Dock180 cytoplasmic expression and advanced cancer stage were found to be independent prognostic factors for short overall survival and disease-free survival (P < 0.05). Exogenous expression of Dock180 by transient transfection enhanced cancer cell migration and invasion, whereas knockdown of Dock180 by an siRNA approach retarded cancer cell migration and invasion in association with down-regulation of matrix metalloproteinase 2. CONCLUSIONS: Our findings suggest that Dock180 contributes to ovarian carcinogenesis and dissemination and is a potential prognostic marker and therapeutic target.
机译:目的:胞质分裂抑制剂I(Dock180)是Rho鸟苷三磷酸(GTPase)的新型鸟嘌呤核苷酸交换因子,对细胞迁移很重要。这项研究的目的是评估Dock180在卵巢癌发生中的作用。方法和结果:通过免疫组织化学,实时聚合酶链反应和蛋白质印迹,在卵巢癌细胞系(n = 5)和卵巢交界性肿瘤的临床样本(n = 5)的细胞核和细胞质中证实了Dock180 RNA和蛋白质的过表达。 21)和浸润性癌(n = 108)与卵巢上皮细胞系(n = 3)和良性囊腺瘤(n = 10)相比(P <0.05)。卵巢癌中Dock180细胞质的高表达(n = 108)与浆液性组织学类型,高级别癌症和晚期(P <0.05)以及不良的总体生存率和无病生存率显着相关(P = 0.004)。使用多变量进展分析,高Dock180细胞质表达和晚期癌症是短期总生存期和无病生存期的独立预后因素(P <0.05)。通过瞬时转染的Dock180外源表达增强癌细胞的迁移和侵袭,而通过siRNA敲除Dock180则与基质金属蛋白酶2的下调相关联,从而延迟了癌细胞的迁移和侵袭。结论:我们的发现表明Dock180有助于卵巢癌的发生。和传播,是潜在的预后标志物和治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号